This clinical trial is focused on studying the treatment of bronchiectasis, a lung condition where the airways become widened, leading to a build-up of mucus that can make the lungs more vulnerable to infection. The study is comparing two different antibiotic treatments to see which is more effective in treating early infections caused by a bacteria called Pseudomonas aeruginosa (PA) in adults with bronchiectasis. The first treatment involves taking an oral antibiotic called ciprofloxacin for 14 days, combined with inhaling a medication called colistimethate sodium (also known as colistin) for 3 months. The second treatment involves a 14-day course of antibiotics given by injection, including a type of antibiotic known as a beta-lactam, along with the same 3-month inhalation of colistimethate sodium.

The purpose of the study is to determine if the first treatment option is not worse than the second in terms of clearing the PA infection over a period of 6 months. Participants will be monitored for 6 months to see if the PA infection is eradicated. The study will also look at other factors such as the time it takes for any worsening of symptoms, the quality of life of participants, and how burdensome the treatment is. Additionally, the study will assess the recurrence of PA and the bacteria’s resistance to ciprofloxacin over time.

Participants will be asked to take part in regular follow-up visits to monitor their health and the effectiveness of the treatment. They will also complete questionnaires to help assess their quality of life and the impact of the treatment. The study aims to provide valuable information on the best way to treat early PA infections in people with bronchiectasis, potentially improving treatment strategies and patient outcomes in the future.